Nucleos(t)ide analogue treatment for patients with hepatiThis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A Nationwide, Multicenter, Retrospective Study

Young Chang, Won Hyeok Choe, Dong Hyun Sinn, Jeong Hoon Lee, Sang Hoon Ahn, Hyewon Lee, Jae Jun Shim, Dae Won Jun, Soo Young Park, Joon Yeul Nam, Eun Ju Cho, Su Jong Yu, Dong Ho Lee, Jeong Min Lee, Yoon Jun Kim, So Young Kwon, Seung Woon Paik, Jung Hwan Yoon

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background. Antiviral treatment for hepatiThis B virus (HBV) e antigen (HBeAg)-positive chronic HBV infection is still controversial. We assessed whether antiviral treatment reduces the risk of liver disease progression in these patients. Methods. This study included consecutive patients in 8 large-volume hospitals in Korea who tested positive for HBeAg and had an HBV DNA level of >20 000 IU/mL, an alanine aminotransferase (ALT) level of <40 IU/L, and no evidence of cirrhosis. Te primary end point was the development of hepatocellular carcinoma (HCC), and the secondary end point was the development of cirrhosis. Results. A total of 484 patients were included: 87 were in the antiviral treatment group, and 397 were in the control group. Baseline liver function was signifcantly more favorable for the control group. Afer matching for propensity score to overcome those di?erences, the antiviral treatment group had a signifcantly reduced risk for HCC (hazard ratio [HR], 0.234; log-rank P =.046) and cirrhosis (HR, 0.235; log-rank P =.015), compared with the control group. Afer balancing the baseline characteristics by using inverse probability weighting, antiviral therapy signifcantly decreased the risk of HCC (HR, 0.189; log-rank P =.004) and cirrhosis (HR, 0.347; log-rank P =.036). Conclusion. Antiviral therapy for patients with HBeAg-positive chronic HBV infection and have a high HBV load reduces the risk of HCC, even if the ALT level is below the upper limit of normal.

Original languageEnglish
Pages (from-to)1407-1414
Number of pages8
JournalJournal of Infectious Diseases
Volume216
Issue number11
DOIs
Publication statusPublished - 2017 Dec 1

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Nucleos(t)ide analogue treatment for patients with hepatiThis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A Nationwide, Multicenter, Retrospective Study'. Together they form a unique fingerprint.

  • Cite this

    Chang, Y., Choe, W. H., Sinn, D. H., Lee, J. H., Ahn, S. H., Lee, H., Shim, J. J., Jun, D. W., Park, S. Y., Nam, J. Y., Cho, E. J., Yu, S. J., Lee, D. H., Lee, J. M., Kim, Y. J., Kwon, S. Y., Paik, S. W., & Yoon, J. H. (2017). Nucleos(t)ide analogue treatment for patients with hepatiThis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A Nationwide, Multicenter, Retrospective Study. Journal of Infectious Diseases, 216(11), 1407-1414. https://doi.org/10.1093/infdis/jix506